Soft Tissue Sarcoma

5 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-OncologycabozantinibSoft Tissue Sarcoma

Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma

By MedXY|Feb 18, 2026

A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,

newsanlotinibchemotherapy

Soft Tissue Sarcoma

Latest news

Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma

Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial